Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from PharmaTimes

08:43 EDT 20th October 2018 | BioPortfolio

Here are the most relevant search results for "PharmaTimes" found in our extensive news archives from over 250 global news sources.

More Information about PharmaTimes on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PharmaTimes for you to read. Along with our medical data and news we also list PharmaTimes Clinical Trials, which are updated daily. BioPortfolio also has a large database of PharmaTimes Companies for you to search.

Showing News Articles 1–25 of 1,000+ from PharmaTimes

Friday 19th October 2018

A bumper networking opportunity

Marketer of the Year will celebrate its 25th anniversary at The Tower Hotel, London on Thursday 15 November, alongside Communications Team of the Year and the all-new Sales Awards.

Have you entered yet?

International Clinical Researcher of the Year is celebrating its 20th anniversary in 2019. If ever there was a time to stand out against the competition and be remembered, it's now!

Individuals from a wide array of companies flock to enter new awards scheme for medical and scientific professionals

There are only two weeks to go until the 31 October deadline, don't miss it -  get your entry in now!Highlighting this important area of work within the pharmaceutical industry, the new Medical & Scientific Excellence Awards are designed to recognise the outstanding achievements of medical and scientific professionals.

Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial

A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.

FDA advisory committee backs Shire’s prucalopride

Shire’s prucalopride has taken a giant leap towards approval after winning the support of an FDA advisory committee for chronic idiopathic constipation.

US filing for ViiV’s two-drug, single pill HIV treatment

ViiV Healthcare has submitted a New Drug Application to the US Food and Drug Administration seeking permission to market a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV.

NICE rejects Lilly’s breast cancer drug Verzenios

As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.

Thursday 18th October 2018

Abeona Therapeutics announces Dr. João Siffert as new CMO

Gov’t to introduce tech standards for the NHS

Health secretary Matt Hancock has unveiled his vision for technology in healthcare, which, he claims, will lay the foundation for a new generation of digital services able to meet the needs of clinicians, patients and managers.

Cell and Gene Therapy Catapult appoints three new board members

NHS green light for Novartis skin cancer combo

The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.

Allergan to file ubrogepant for migraine early next year

Allergan is gearing up to file its oral CGRP receptor ubrogepant in the US for the treatment of migraine, following the success and completion of two safety studies.

Novartis buys Endocyte for $2.1 billion

Novartis has signed a deal to acquire US biopharma Endocyte, securing itself access to novel radiopharmaceutical programmes “with significant sales potential”.

Wednesday 17th October 2018

Karuna appoints Jeff Jonas to Board of Directors

Sponsors

Where & When

London’s health and care system hampering STP progress, finds report

London’s “complex and cluttered” health and care system is holding back plans to improve the health of its population, finds a new independent report from The King’s Fund.

AZ/MSD’s Lynparza assigned Orphan status in US

AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.

Another Humira biosimilar hits EU shores

Samsung Bioepis has announced the European launch of Humira biosimilar Imraldi, as NHS chiefs tell Trusts to ensure they are ready to realise the potential savings from using cheaper versions of the world’s biggest selling drug.

UK launch for first eosinophilic oesophagitis drug

Dr Falk Pharma has launched Jorveza - the first globally licensed drug approved for eosinophilic oesophagitis - across the UK.

Pfizer’s Talzenna cleared for breast cancer

US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.

Tuesday 16th October 2018

Ashfield appoints new global commercial director

Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials

Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all their primary and secondary endpoints.

Amgen begins rolling out Humira biosimilar in the EU

Amgen has begun launching Amgevita, the first biosimilar of AbbVie’s anti-inflammatory blockbuster Humira to win approval in Europe, across the region.

NHS Trafford CCG placing team of pharmacists in care homes

NHS Trafford Clinical Commissioning Group is placing a team of pharmacists to work across care homes in the borough to boost access to healthcare in the community.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks